COMP <GO>
ALEC vs SCTX // EV/EBITDA & P/E VALUATION
Alector Inc. (NASDAQ) VS. Scribe Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALEC 2
— SCTX 0
■ METRIC PARITY
LAST: $2.24 (-0.44%) • MKT CAP: $332.1M
valuation
—
LAST: $17.44 (-0.57%) • MKT CAP: $330.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALEC VS. SCTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALEC | SCTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 36.8 | +23.65 | ALEC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $332.1M | $330.2M | $1.9M | ALEC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALEC REV | SCTX REV | ALEC GROSS % | SCTX GROSS % | ALEC FCF | SCTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.0M | $0 | — | — | -$184.1M | — |
| FY 2024 | $100.6M | — | — | — | -$231.2M | — |
| FY 2023 | $97.1M | — | — | — | -$184.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALEC // BETA —
SCTX // BETA —